ClinicalTrials.gg

Program

aficamten

Also written as “Aficamten”, “BAY3723113” and “Aficamten (5 - 20 mg)”.

Its studies are mostly in Cardiomyopathy, Hypertrophic, led by 3 companies.

Furthest: phase 3, since Apr 9, 202111 company-led studies, 4 open or runningNext primary completion: Mar 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Cytokinetics83 open or runningphase 3since Apr 9, 2021Dec 3, 2018Mar 2029phase 3 · NCT04848506
Corxel Pharmaceuticals20 open or runningphase 3since Oct 25, 2023Mar 3, 2021none ahead
Bayer11 open or runningphase 3since Jun 10, 2025Jun 10, 2025none ahead

Also a collaborator on its studies: Sanofi.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 3, 2018First study: phase 1 study in Cardiomyopathy, HypertrophicNew to CytokineticsCytokinetics · NCT03767855 · 114 enrolled · United States
  2. Jan 3, 2020Phase 2 study in Cardiomyopathy, HypertrophicCytokinetics · NCT04219826 · 96 enrolled · United States, Italy, Netherlands and more
  3. Mar 3, 2021Corxel Pharmaceuticals's first study: phase 1 study in Cardiomyopathy, HypertrophicNew to Corxel PharmaceuticalsCorxel Pharmaceuticals · NCT04783766 · 28 enrolled · China
  4. Apr 9, 2021Phase 3 study in Cardiomyopathy, HypertrophicCytokinetics · NCT04848506 · 900 planned · United States, Argentina, Australia and more
  5. Dec 23, 2021Phase 3 study in Cardiomyopathy, HypertrophicCytokinetics · NCT05186818 · 282 enrolled · United States, China, Czechia and more
  6. Mar 2, 2023Phase 3 study in Cardiomyopathy, HypertrophicCytokinetics · NCT05767346 · 175 enrolled · United States, Brazil, Canada and more
  7. Jun 7, 2023Phase 1 study in Healthy ParticipantsCytokinetics · NCT05924815 · 44 enrolled · United States
  8. Aug 31, 2023Phase 3 study in Symptomatic Non-Obstructive Hypertrophic CardiomyopathyCytokinetics · NCT06081894 · 500 enrolled · United States, Argentina, Australia and more
  9. Oct 25, 2023Phase 3 study in Cardiomyopathy, HypertrophicCorxel Pharmaceuticals · NCT06116968 · 40 enrolled · China
  10. May 9, 2024Phase 3 study in PediatricCytokinetics · NCT06412666 · 65 enrolled · United States, Canada, Italy and more
  11. Jun 10, 2025Bayer's first study: phase 3 study in Cardiomyopathy, HypertrophicNew to BayerBayer · NCT07023341 · 36 enrolled · Japan
  12. Oct 13, 2026Primary completion moved from 2028-03 to 2029-03Date moved laterphase 3 · +12 months · NCT04848506

Ahead

  1. Mar 2029Primary completion: phase 3 study in Cardiomyopathy, HypertrophicCytokinetics · NCT04848506
  2. Jan 2030Primary completion: phase 3 study in PediatricCytokinetics · NCT06412666

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07023341Cardiomyopathy, Hypertrophic · Japan3Active, not recruitingBayerJul 14, 202636
NCT06412666Pediatric · United States, Canada, Italy and more3Active, not recruitingCytokineticsJan 203065
NCT06116968Cardiomyopathy, Hypertrophic · China3CompletedCorxel PharmaceuticalsOct 20, 202540
NCT06081894Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy · United States, Argentina, Australia and more3Active, not recruitingCytokineticsAug 31, 2026500
NCT05924815Healthy Participants · United States1CompletedCytokineticsNov 14, 202344
NCT05767346Cardiomyopathy, Hypertrophic · United States, Brazil, Canada and more3CompletedCytokineticsFeb 28, 2025175
NCT05186818Cardiomyopathy, Hypertrophic · United States, China, Czechia and more3CompletedCytokineticsNov 10, 2023282
NCT04848506Cardiomyopathy, Hypertrophic · United States, Argentina, Australia and more3By invitationCytokineticsMar 2029900
NCT04783766Cardiomyopathy, Hypertrophic · China1CompletedCorxel PharmaceuticalsAug 5, 202128
NCT04219826Cardiomyopathy, Hypertrophic · United States, Italy, Netherlands and more2CompletedCytokineticsFeb 28, 202396
NCT03767855Cardiomyopathy, Hypertrophic · United States1CompletedCytokineticsJan 3, 2020114

How it is read

Names in the registry

  • “Aficamten”, 4 entries
  • “BAY3723113”, 1 entry
  • “Aficamten (5 - 20 mg)”, 1 entry
  • “Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)”, 1 entry
  • “Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
aficamten (Cytokinetics): development program | ClinicalTrials.gg